ORG 39970

Drug Profile

ORG 39970

Latest Information Update: 20 Oct 2009

Price : $50

At a glance

  • Originator Organon
  • Class
  • Mechanism of Action Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Andropause; Female genital diseases

Most Recent Events

  • 19 Nov 2007 Organon has been acquired by Schering-Plough
  • 28 Oct 2005 Phase-II clinical trials in Andropause in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top